Raymond James & Associates Reduces Holdings in Integer Holdings Co. (NYSE:ITGR)

Raymond James & Associates trimmed its holdings in Integer Holdings Co. (NYSE:ITGR) by 6.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 49,311 shares of the medical equipment provider’s stock after selling 3,185 shares during the period. Raymond James & Associates owned approximately 0.15% of Integer worth $6,410,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Contravisory Investment Management Inc. raised its position in Integer by 55.9% in the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares during the period. Quest Partners LLC lifted its position in shares of Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Integer during the 1st quarter worth approximately $106,000. Finally, Innealta Capital LLC acquired a new position in shares of Integer in the second quarter worth $110,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ITGR shares. Piper Sandler restated an “overweight” rating and set a $140.00 price target (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. Bank of America increased their price objective on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Truist Financial lowered their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday, October 25th. Benchmark raised their price target on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Oppenheimer started coverage on shares of Integer in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Trading Down 4.4 %

NYSE:ITGR opened at $124.25 on Friday. The company has a market capitalization of $4.16 billion, a PE ratio of 42.99, a price-to-earnings-growth ratio of 1.80 and a beta of 1.08. Integer Holdings Co. has a 52-week low of $79.68 and a 52-week high of $133.53. The stock has a fifty day simple moving average of $128.01 and a 200-day simple moving average of $121.29. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.31% and a return on equity of 11.48%. The company had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. During the same quarter in the prior year, the firm earned $1.27 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities research analysts expect that Integer Holdings Co. will post 5.3 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.